Hope on the horizon for rare kidney disease
Loosening of clinical requirements has encouraged more projects into the IgA nephropathy pipeline, with a steroid–based approach from Sweden’s Calliditas looking…
Small and mid-cap share price gains make up for majors
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.
The big launches of 2014 – where are they now?
The drugs of 2014 that went supernova and those that failed to make orbit.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.